RECORDED WEBINAR

Amylin as a Novel Diabetes and Obesity Therapy

     

OVERVIEW

Explore this recorded session from the American Diabetes Association’s 2026 Scientific Sessions on amylin-based therapies for obesity and diabetes, featuring research on amylin’s biology and brain mechanisms, clinical trial findings, and potential benefits and limitations. Hear how these treatments may be used alone or alongside GLP-1 therapies, future roles in obesity care, and open questions for research and clinical practice.

LEARNING OBJECTIVES

  • Recognize the physiologic and therapeutic rationale for amylin-based approaches to obesity treatment.
  • Identify evidence regarding the efficacy, safety, and tolerability of amylin-based therapies. 
  • Identify clinical and practical considerations relevant to the potential use of amylin-based therapies in obesity management. 

EXPIRATION DATE

December 31, 2027

FACULTY 

W. Timothy Garvey, MD, MACE, MABOM
Carel LeRoux, MD, PhD
Thomas Lutz, PhD

 

This program is funded in part through an unrestricted educational grant from Novo Nordisk.

Note: You do not need to be an ADA professional member to access our free continuing education programs. Simply create a free account and start exploring 70+ free CE courses. Login to get started!

Android App Download IOS App Download Powered By